Marcy l'Etoile, France - June 27, 2006. bioMérieux, a global leader in the field of in vitro diagnostics, today announced the closing of the sale of its hemostasis range of products to Trinity Biotech plc.
For bioMérieux, the total value of the deal could amount to nearly $60 million, including the proceeds from assets sold, receivables to be collected and $5.5 million of the transaction contingent on meeting the business’ 2006 objectives. bioMérieux will manufacture the products on behalf of Trinity Biotech plc for a 12 month transitory period. The capital gain should cover the related restructuring expense and the remaining fixed costs.
The transaction is perfectly aligned with the company’s strategic commitment to focusing on operations related to infectious diseases, cancer and cardiovascular diseases as well as to industrial applications.